Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

About the trial

Sponsor

Alliance for Clinical Trials in Oncology

Tested

Pembrolizumab (biological), Tivozanib (drug), Biospecimen Collection (procedure), MRI (procedure), Computed Tomography (procedure), Biopsy (procedure), Questionnaire Administration (other)

Dates

Started 2025-03-14; completion 2037-11

Results posted

Not yet

This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals tumor cells to multiply. This helps stop the spread of tumor cells. Giving pembrolizumab and tivozanib together may work better than pembrolizumab alone in treating patients with RCC.

From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Aveo Pharmaceuticals, Inc. reported $189,723 in research payments for this study in 2025 (2 payments).

Products named: Fotivda

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.